Therefore, a combination therapy using two or more chemotherapeutic drugs or inhibitors to increase the sensitivity of cancer cells to cytotoxic anti-cancer agents could be used to treat p53 mutated cancers, and some animal models have revealed promising outcomes in tumor regression when wild-type p53 was activated in p53 mutated cancers [9]. This evidence concerns the gene TP53 and neoplasm.